Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Badalamenti

Showing results (521-530 of 550) with videos related to

Pageof 55
Sort By:
Gut|June 30, 2021
Artificial intelligence and colonoscopy experience: lessons from two randomised trialsAlessandro Repici, Marco Spadaccini, Giulio Antonelli, et al.
Cancers|April 3, 2021
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma GroupEmanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, et al.
Journal of Endocrinological Investigation|August 18, 2020
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)F Panzuto, M Maccauro, D Campana, et al.
Lancet (London, England)|November 27, 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D Demetri, Peter Reichardt, Yoon-Koo Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma GroupL D'Ambrosio, A Merlini, A Brunello, et al.
Frontiers in Oncology|December 26, 2022
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a <i>post-hoc</i> analysisEmanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, et al.
Breast Cancer Research and Treatment|February 12, 2022
Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analysesE Palassini, O Mir, G Grignani, et al.
Plos One|January 4, 2014
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyDaniele Santini, Giuseppe Procopio, Camillo Porta, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomasAlberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
Scientific Reports|December 23, 2015
Natural History of Non-Small-Cell Lung Cancer with Bone MetastasesDaniele Santini, Santini Daniele, Sandro Barni, et al.
Pageof 55

Showing results (521-530 of 550) with videos related to

Sort By:
Pageof 55
Gut|June 30, 2021
Artificial intelligence and colonoscopy experience: lessons from two randomised trialsAlessandro Repici, Marco Spadaccini, Giulio Antonelli, et al.
Cancers|April 3, 2021
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma GroupEmanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, et al.
Journal of Endocrinological Investigation|August 18, 2020
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)F Panzuto, M Maccauro, D Campana, et al.
Lancet (London, England)|November 27, 2012
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialGeorge D Demetri, Peter Reichardt, Yoon-Koo Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2025
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma GroupL D'Ambrosio, A Merlini, A Brunello, et al.
Frontiers in Oncology|December 26, 2022
Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a <i>post-hoc</i> analysisEmanuela Palmerini, Roberta Sanfilippo, Giovanni Grignani, et al.
Breast Cancer Research and Treatment|February 12, 2022
Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analysesE Palassini, O Mir, G Grignani, et al.
Plos One|January 4, 2014
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyDaniele Santini, Giuseppe Procopio, Camillo Porta, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomasAlberto Bongiovanni, Chiara Liverani, Flavia Foca, et al.
Scientific Reports|December 23, 2015
Natural History of Non-Small-Cell Lung Cancer with Bone MetastasesDaniele Santini, Santini Daniele, Sandro Barni, et al.
Pageof 55